top of page

AMICROBE

News

Amicrobe, Inc., Developer of Novel Synthetic Biologics, Adds Fifth U.S. Patent to Intellectual Property Portfolio

Today, Amicrobe, Inc. announced the issue of U.S. Patent No. 11,285,189, entitled "Compositions and uses of locally applied antimicrobials with enhanced performance and safety." Amicidins are synthetic biologics designed to be safe for individuals and the environment – this new patent acknowledges the Company's inventive approach in achieving this important goal. Amicrobe's fifth U.S. patent brings its intellectual property portfolio to 26 issued / allowed patents worldwide, further protecting its Amicidin technology platform and innovative product candidates.  The full press release can be viewed here.

bottom of page